

# Don't miss the CARDIOVASCULAR EXPERT THEATER SESSIONS

ENJOY A COMPLIMENTARY LUNCH\* WHILE LEARNING THE LATEST ADVANCES  
IN CARDIOVASCULAR PRACTICES, SERVICES AND TECHNOLOGIES.

SUNDAY

BOOTH	SESSION START/END TIME	SUPPORTER	TITLE
701	11:15 AM – Noon	Amgen, Inc.	Interpreting Measures of Clinical Effectiveness in Cardiovascular Outcome Trials
3661	11:15 AM – Noon	Janssen Pharmaceuticals	Thrombosis: AFib & DVT/PE - An Exploration in Risk Reduction
	12:30 PM – 1:15 PM	Novartis	Putting Guidelines Into Practice: New Recommendations for Optimal Treatment of Heart Failure With Reduced Ejection Fraction (HF rEF)
	3:00 PM – 3:45 PM	Novartis	Dyslipidemia and Inflammation: Emerging Strategies for Reducing Residual Risk in Patients With a History of Myocardial Infarction (MI)
751	11:15 AM – Noon	Sanofi - Regeneron	PRALUENT® (alirocumab) Injection: Long-Term Efficacy and Safety
	12:30 PM – 1:15 PM	Amgen, Inc.	Repatha®(evolocumab): A Focused Clinical Review

MONDAY

BOOTH	SESSION START/END TIME	SUPPORTER	TITLE
701	Noon – 12:45 PM	Sanofi - Regeneron	PRALUENT® (alirocumab) Injection: Efficacy and Safety With Two Different Dosing Options
	1:15 PM – 2:00 PM	Amgen, Inc.	Repatha®(evolocumab): A Focused Clinical Review
3661	10:15 AM – 11:00 AM	Lundbeck	Doctor, I'm Dizzy: Clinical Perspectives of Neurogenic Orthostatic Hypotension
	Noon – 12:45 PM	Allergan	Treatment Approaches for Hypertension
	1:15 PM – 2:00 PM	Boehringer Ingelheim	Moving Forward with Reverse, a Multi-Specialty Perspective
	3:15 PM – 4:00 PM	Novartis	The Balancing Act of AHF Care: A Focus on Treatment, Outcomes, and Economics
751	Noon – 12:45 PM	Amgen, Inc.	From Particles to Plaque: Mechanisms and Measurement of Atherosclerosis
	1:15 PM – 2:00 PM	Novartis	Addressing Treatment Priorities in Heart Failure

TUESDAY

BOOTH	SESSION START/END TIME	SUPPORTER	TITLE
701	Noon – 12:45 PM	Amgen, Inc.	From Particles to Plaque: Mechanisms and Measurement of Atherosclerosis
	1:15 PM – 2:00 PM	Relypsa, Inc.	Dietary and Pharmacologic Management of Electrolyte Disorders in Heart Failure
3661	Noon – 12:45 PM	Boehringer Ingelheim and Medtronic	The Diagnosis and Management of Atrial Fibrillation: Working Together to Reduce Stroke Risk in NVAf
	1:15 PM – 2:00 PM	Novartis	Roles of In-Hospital Worsening Heart Failure and End Organ Damage in Long-Term Outcomes
751	Noon – 12:45 PM	Daiichi Sankyo, Inc.	Anticoagulation in Perspective
	1:15 PM – 2:00 PM	Aralez Pharmaceuticals	Cardioprotection vs Gastrotoxicity: Finding a Balance to Advance Secondary Prevention of Cardiovascular Events With Aspirin

\*Provided to attendees by the American Heart Association.

This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

[scientificsessions.org](http://scientificsessions.org)